

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

				_		
	APPLICATION NO.	Fil	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/897,776		06/29/2001		Patrick S. Schnable	08411-027001 /ISURF 02424	1907
	26191	7590	12/24/2002			
FISH & RICHARDSON P.C. 3300 DAIN RASCHER PLAZA 60 SOUTH SIXTH STREET MINNEAPOLIS, MN 55402					EXAMI	NER
			REET		MCKELVEY, TERRY ALAN	
	MINNEAPOL	15, MN	55402		ART UNIT	PAPER NUMBER
					1636	\ \ \
					DATE MAILED: 12/24/2002	(9)

Please find below and/or attached an Office communication concerning this application or proceeding.

•	Application No.	Applicant(s)						
	09/897,776	SCHNABLE ET AL.						
Office Action Summary	Examiner	Art Unit						
	Terry A. McKelvey	1636						
The MAILING DATE of this communication appeared for Reply	The MAILING DATE of this communication appears on the cover sheet with the correspondence address							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE one MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).  Status								
1) Responsive to communication(s) filed on	_·							
2a) This action is FINAL. 2b) Thi	s action is non-final.							
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.								
Disposition of Claims								
4)⊠ Claim(s) <u>1-29</u> is/are pending in the application								
4a) Of the above claim(s) is/are withdrawn from consideration.								
5)  Claim(s) is/are allowed.								
6) ☐ Claim(s) is/are rejected.								
7) Claim(s) is/are objected to.								
8) Claim(s) <u>1-29</u> are subject to restriction and/or election requirement.  Application Papers								
9) The specification is objected to by the Examiner.								
10) The drawing(s) filed on is/are: a) □ accepted or b) □ objected to by the Examiner.								
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
11) ☐ The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved by the Examiner.								
If approved, corrected drawings are required in reply to this Office action.								
12)☐ The oath or declaration is objected to by the Examiner.								
Priority under 35 U.S.C. §§ 119 and 120								
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).								
a) ☐ All b) ☐ Some * c) ☐ None of:								
<ol> <li>Certified copies of the priority documents</li> </ol>	s have been received.							
2. Certified copies of the priority documents	s have been received in Applicati	on No						
<ul> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>								
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).								
<ul> <li>a) ☐ The translation of the foreign language provisional application has been received.</li> <li>15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.</li> </ul>								
Attachment(s)								
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal I	(PTO-413) Paper No(s) Patent Application (PTO-152)						
S. Patent and Trademark Office								

Application/Control Number: 09/897,776 Page 2

Art Unit: 1636

## DETAILED ACTION

## Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-20 and 26, drawn to isolated nucleic acid comprising 3 start codons, vector, cell and complement, classified in class 536, subclass 23.1 and subclass 435, subclasses 320.1, 325, 243, and 410.
- II. Claims 21-25 and 27, drawn to method for determining the presence or absence of an open reading frame and method for isolating a polypeptide, classified in class 435, subclasses 6 and 69.1.
- III. Claim 28, drawn to isolated nucleic acid having the sequence of SEQ ID NO:15, classified in class 536, subclass 23.1.
- IV. Claim 29, drawn to isolated nucleic acid having the sequence of SEQ ID NO:16, classified in class 536, subclass 23.1.

The inventions are independent and/or distinct, each from the other because of the following reasons:

Inventions of Group I and Group II are related as product and process of use. The inventions can be shown to be distinct

Application/Control Number: 09/897,776

Art Unit: 1636

if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the product as claimed can be used in a materially different process, for overexpressing genes.

Page 3

The nucleic acid, etc of Group I and the nucleic acids of Groups III-IV are chemically, biologically, and functionally distinct from each other and thus one does not render the other obvious. The products of one group are not needed to produce the products of the other groups because they are drawn to independent nucleic acids of different sequences. Therefore, the inventions of the three groups are capable of supporting separate patents.

Inventions of Groups II-IV are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case, the nucleic acids of Groups III-IV are not used or produced in the methods of Group II. The nucleic acids of Groups III-IV are drawn to

Application/Control Number: 09/897,776 Page 4

Art Unit: 1636

sequences different from each other and thus are independent sequences.

Because these inventions are independent and/or distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, and the search required for each of Groups I and III-IV are not required for the other groups with regard to the nonpatent literature search, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Application/Control Number: 09/897,776 Page 5

Art Unit: 1636

## Conclusion

Certain papers related to this application may be submitted to Art Unit 1636 by facsimile transmission. The faxing of such papers must conform with the notices published in the Official Gazette, 1156 OG 61 (November 16, 1993) and 1157 OG 94 (December 28, 1993) (see 37 C.F.R. § 1.6(d)). The official fax telephone numbers for the Group are (703) 308-4242 and (703) 305-3014.

NOTE: If Applicant does submit a paper by fax, the original signed copy should be retained by applicant or applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers in the Office.

Any inquiry concerning rejections or other major issues in this communication or earlier communications from the examiner should be directed to Terry A. McKelvey whose telephone number is (703) 305-7213. The examiner can normally be reached on Monday through Friday, except for Wednesdays, from about 7:30 AM to about 6:00 PM. A phone message left at this number will be responded to as soon as possible (i.e., shortly after the examiner returns to his office).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Remy Yucel, can be reached at (703) 305-1998.

Application/Control Number: 09/897,776

Art Unit: 1636

Page 6

of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Any inquiry of a general nature or relating to the status

Terry A. McKelvey, Ph.D. Primary Examiner

Art Unit 1636

December 20, 2002